This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

II. SULFANILAMIDE IN THE TREATMENT OF EXPERIMENTAL STREPTOCOCCIC MENINGITIS

PAUL E. ADOLPH, M.D.; JOHN S. LOCKWOOD, M.D.

Arch Otolaryngol. 1938;27(5):535-551.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the introduction of sulfanilamide (paraaminobenzenesulfonamide), many reports¹ have appeared concerning the successful treatment of meningitis due to Streptococcus haemolyticus in man. This is of considerable importance, since the mortality rate for all types of streptococcic meningitis has been estimated by Gray² at 97 per cent with means of treatment other than sulfanilamide. Any therapy that gives promise of materially lowering this mortality rate is indeed welcome, even if it is accompanied by minor untoward effects, such as those indicated by recent reports on toxic manifestations due to sulfanilamide.³

A review of the literature reveals that in most of the animal experiments in which sulfanilamide was used to treat infection due to Str. haemolyticus, the infection was confined to tissues other than the meninges;⁴ i. e., subcutaneous infection, intraperitoneal infection or septicemia was treated. We are not aware of any reports of experiments in which sulfanilamide was used to treat . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA

From the Laboratory of Surgical Bacteriology, Harrison Department of Surgical Research, University of Pennsylvania School of Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?